NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I-IIIA) Non-Small Cell Lung Cancer

被引：7
|
作者：
Garcia Campelo, R. [1 ]
Forde, P. [2 ]
Weder, W. [3 ]
Spicer, J. [4 ]
He, P. [5 ]
Hamid, O. [5 ]
Martinez, P. [5 ]
Cascone, T. [6 ]
机构：
[1] Univ Hosp A Coruna, Coruna, Spain
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Zurich, Thorac Sugery, Zurich, Switzerland
[4] McGill Univ, Montreal, AB, Canada
[5] Astrazeneca, Gaithersburg, MD USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
early-stage NSCLC; neoadjuvant treatment; checkpoint inhibition;
D O I：
10.1016/j.jtho.2019.08.1533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-28
引用
收藏
页码：S719 / S719
页数：1
相关论文
共 50 条
  • [1] Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
    Spicer, J.
    Cascone, T.
    Kar, G.
    Zheng, Y.
    Blando, J.
    Tan, T. H.
    Cheng, M.
    Mager, R.
    Hamid, O.
    Soo-Hoo, Y.
    Forde, P. M.
    Weder, W.
    Campelo, M. R. Garcia
    Grenga, I.
    Kumar, R.
    McGrath, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S971 - S971
  • [2] Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
    Zhang, Peng
    Dai, Jie
    Sun, Fenghuan
    Xia, Haoran
    He, WenXin
    Duan, Liang
    Liu, Ming
    Zhao, Deping
    Zhu, Yuming
    Jiang, Gening
    ANNALS OF THORACIC SURGERY, 2022, 114 (03): : 949 - 958
  • [3] Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Xu, Feng
    Hui, Zhenzhen
    Zhao, Gang
    Liu, Jie
    Zhang, Huan
    Zeng, Ziqing
    Zhang, Ran
    Provencio, Mariano
    Ren, Xiubao
    You, Jian
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (05) : 2193 - +
  • [4] Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.
    Chaft, Jamie E.
    Forde, Patrick M.
    Smith, Kellie Nicole
    Anagnostou, Valsamo
    Cottrell, Tricia
    Taube, Janis M.
    Rekhtman, Natasha
    Merghoub, Taha
    Jones, David Randolph
    Hellmann, Matthew David
    Yang, Stephen C.
    Broderick, Stephen
    Rusch, Valerie W.
    Velculescu, Victor E.
    Topalian, Suzanne Louise
    Pardo, Drew M.
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] The role of chemotherapy in early-stage (stage I and II) resectable non-small cell lung cancer
    Pisters, KMW
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (04) : 274 - 279
  • [6] Neoadjuvant chemotherapy in early-stage non-small cell lung cancer
    Salva, Francesc
    Felip, Enriqueta
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (05) : 398 - 402
  • [7] Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer
    Betticher, DC
    Rosell, R
    LUNG CANCER, 2004, 46 : S23 - S32
  • [8] Treatment of resectable stage IIIA non-small cell lung cancer
    Cardenal, Felipe
    Palmero, Ramon
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15
  • [9] Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care
    Jessica S. Donington
    Annals of Surgical Oncology, 2022, 29 : 5344 - 5346
  • [10] Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care
    Donington, Jessica S.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (09) : 5344 - 5346
12345